Denali Therapeutics Quarterly Income Statement
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Denali Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Denali Therapeutics generated $3.6 million in revenue, up 0.0% from the same quarter a year earlier. Denali Therapeutics reported a net loss of $127.6 million, compared with a loss of $124.1 million a year earlier. Gross margin was 97.4% and operating margin -3622.1%.
Diluted earnings per share came in at -$0.68.
Summary generated from market data by MetaCap's automated system. Methodology
Denali Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.60M | — | — | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 1.27M |
| Revenue growth (YoY) | — | — | — | — | — | — | — | -100.00% | -100.00% | -100.00% | -100.00% | -64.40% |
| Cost of Revenue | 93.00K | — | — | — | 0 | — | — | — | — | — | — | — |
| Gross Profit | 3.51M | — | — | — | 0 | — | — | — | — | — | — | — |
| Operating Expenses | 134.05M | 137.36M | 137.37M | 137.43M | 134.96M | 145.58M | 129.85M | 123.19M | 116.59M | 132.25M | 132.57M | 115.06M |
| Research & Development | 97.02M | 103.85M | 97.91M | 101.95M | 102.70M | 116.23M | 99.79M | 98.24M | 91.40M | 107.02M | 107.80M | 89.74M |
| Selling, General & Admin | 36.28M | — | — | — | 32.27M | — | — | — | — | — | — | — |
| Operating Income | -130.54M | -137.36M | -137.37M | -137.43M | -134.96M | -145.58M | -129.85M | -123.19M | -116.59M | -117.72M | -132.57M | -113.80M |
| Other Income (Expense) | — | — | — | — | — | — | — | — | — | — | 13.13M | 14.44M |
| Income Tax | — | — | — | — | — | — | — | — | — | — | 30.00K | 0 |
| Net Income | -127.55M | -128.45M | -128.55M | -126.90M | -124.12M | -132.97M | -114.75M | -107.19M | -99.03M | -101.80M | -119.47M | -99.35M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | -154.00% | — | — | — |
| EPS (Basic) | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 | -0.63 | -0.59 | -0.68 | -0.88 | -0.72 |
| EPS (Diluted) | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 | -0.63 | -0.59 | -0.68 | -0.84 | -0.72 |
| Shares Outstanding (Basic) | 187.31M | 186.64M | — | 172.42M | 171.45M | 171.22M | — | 169.46M | 168.83M | 149.40M | — | 137.64M |
| Shares Outstanding (Diluted) | 187.31M | 186.64M | — | 172.42M | 171.45M | 171.22M | — | 169.46M | 168.83M | 149.40M | — | 137.64M |
| EBITDA | -126.97M | -134.51M | -134.50M | -134.49M | -131.92M | -143.25M | -127.99M | -121.35M | -114.65M | -115.55M | -130.40M | -111.58M |
| Gross Margin | 97.42% | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -3622.11% | — | — | — | — | — | — | — | — | — | — | -8981.45% |
| Net Margin | -3539.21% | — | — | — | — | — | — | — | — | — | — | -7841.59% |
This table shows 12 quarterly periods of Denali Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow DNLI's reporting calendar. What is a income statement?